Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: application for allogeneic transplantation.

International Journal of Hematology
Hiroki TorikaiToshitada Takahashi

Abstract

It has been shown that allogeneic hematopoietic stem cell transplantation (HSCT) can be one of the therapeutic options for patients with metastatic solid tumors, such as renal cancer. However, the development of relatively severe GVHD seems to be necessary to achieve tumor regression in the current setting. Thus, it is crucial to identify minor histocompatibility antigens (mHags) only expressed in tumor cells but not GVHD target organs. In this study, we examined whether three mHags: ACC-1 and ACC-2 encoded by BCL2A1, and HA-1 encoded by HMHA1, could serve as such targets for melanoma. Real-time PCR and immunohistochemical analysis revealed that the expression of both BCL2A1and HMHA1 in melanoma cell lines and primary melanoma cells was comparable to that of hematopoietic cells. Indeed, melanoma cell lines were efficiently lysed by cytotoxic T lymphocytes specific for ACC-1, ACC-2, and HA-1. Our data suggest that targeting mHags encoded not only by HMHA1, whose aberrant expression in solid tumors has been reported, but also BCL2A1 may bring about beneficial selective graft-versus-tumor effects in a population of melanoma patients for whom these mHags are applicable.

References

Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M B AtkinsS A Rosenberg
Mar 21, 2002·Proceedings of the National Academy of Sciences of the United States of America·Andrew I SuJohn B Hogenesch
Apr 20, 2002·Transplantation·Nobuharu FujiiMine Harada
Sep 5, 2002·International Journal of Cancer. Journal International Du Cancer·Toshiro KurokawaAndreas Mackensen
Oct 31, 2002·Seminars in Oncology·Jean-Pascal MachielsMarie Marchand
May 29, 2003·The Journal of Experimental Medicine·Yoshiki AkatsukaToshitada Takahashi
Jun 14, 2003·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Mikinori MiyazakiToshitada Takahashi
May 4, 2004·Nature Reviews. Cancer·Marie Bleakley, Stanley R Riddell
Aug 18, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael R BishopRonald Gress
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark E DudleySteven A Rosenberg
Jun 15, 2005·Expert Opinion on Biological Therapy·Alain Ravaud, Marie-Sarah Dilhuydy
Mar 23, 2006·Annual Review of Immunology·Thierry BoonPierre van der Bruggen
Jan 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David F McDermott
May 25, 2007·Cancer Science·Yoshiki AkatsukaToshitada Takahashi

❮ Previous
Next ❯

Citations

Feb 9, 2011·Immunology and Cell Biology·Marie Bleakley, Stanley R Riddell
Dec 25, 2010·Acta Microbiologica Et Immunologica Hungarica·Joseph G Sinkovics
Nov 1, 2014·Melanoma Management·Léon C van KempenAlan Spatz
Jun 26, 2020·Frontiers in Pediatrics·Corinne SummersMarie Bleakley
Mar 19, 2020·Frontiers in Immunology·Yoshiki Akatsuka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.